The new oral anticoagulants dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban may be linked to a higher risk of gastrointestinal bleeding compared with standard treatment, according to a study in the journal Gastroenterology. Researchers reviewed information from 43 randomized trials and concluded that more trials are needed to clarify the link.

Related Summaries